 Bradley Corr
Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 20 | 2025 | 201 | 6.740 |
Why?
| | Neoplasm Recurrence, Local | 10 | 2025 | 1079 | 2.490 |
Why?
| | Ovarian Neoplasms | 12 | 2025 | 565 | 2.420 |
Why?
| | Carcinoma, Endometrioid | 3 | 2022 | 50 | 1.840 |
Why?
| | Phenylurea Compounds | 4 | 2025 | 97 | 1.390 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2025 | 1692 | 1.360 |
Why?
| | beta Catenin | 4 | 2023 | 253 | 1.330 |
Why?
| | Quinolines | 4 | 2025 | 178 | 1.330 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2025 | 804 | 1.200 |
Why?
| | Lymph Nodes | 2 | 2018 | 491 | 0.890 |
Why?
| | Uterine Cervical Neoplasms | 6 | 2024 | 257 | 0.850 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2025 | 115 | 0.850 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 192 | 0.760 |
Why?
| | Indoles | 1 | 2025 | 412 | 0.750 |
Why?
| | Wnt Proteins | 1 | 2021 | 133 | 0.660 |
Why?
| | Aged, 80 and over | 22 | 2025 | 7635 | 0.650 |
Why?
| | Mutation | 6 | 2025 | 3958 | 0.620 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2025 | 528 | 0.620 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2018 | 80 | 0.530 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1313 | 0.530 |
Why?
| | Antineoplastic Agents | 5 | 2025 | 2129 | 0.510 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 63 | 0.500 |
Why?
| | Female | 44 | 2025 | 73304 | 0.500 |
Why?
| | Middle Aged | 31 | 2025 | 33479 | 0.490 |
Why?
| | Keratin-5 | 1 | 2015 | 50 | 0.470 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 49 | 0.470 |
Why?
| | Venous Thromboembolism | 2 | 2020 | 316 | 0.470 |
Why?
| | Cisplatin | 2 | 2023 | 320 | 0.460 |
Why?
| | Aged | 26 | 2025 | 23961 | 0.450 |
Why?
| | Hysterectomy | 4 | 2019 | 129 | 0.440 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 78 | 0.410 |
Why?
| | Immunoconjugates | 2 | 2024 | 114 | 0.400 |
Why?
| | Camptothecin | 2 | 2024 | 116 | 0.400 |
Why?
| | Neoplasm Grading | 4 | 2025 | 307 | 0.400 |
Why?
| | Microsatellite Instability | 2 | 2025 | 42 | 0.390 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 104 | 0.380 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1276 | 0.380 |
Why?
| | Bile Duct Neoplasms | 1 | 2013 | 124 | 0.380 |
Why?
| | Humans | 48 | 2025 | 137585 | 0.370 |
Why?
| | Genital Neoplasms, Female | 3 | 2024 | 90 | 0.360 |
Why?
| | Lymph Node Excision | 3 | 2018 | 171 | 0.360 |
Why?
| | Adult | 24 | 2025 | 37929 | 0.340 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2025 | 801 | 0.340 |
Why?
| | Molecular Targeted Therapy | 2 | 2025 | 411 | 0.330 |
Why?
| | Maytansine | 2 | 2025 | 16 | 0.290 |
Why?
| | Bevacizumab | 3 | 2025 | 138 | 0.260 |
Why?
| | Immunohistochemistry | 2 | 2023 | 1738 | 0.240 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 35 | 0.240 |
Why?
| | Cell Survival | 2 | 2021 | 1120 | 0.230 |
Why?
| | Folate Receptor 1 | 1 | 2024 | 15 | 0.230 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3412 | 0.230 |
Why?
| | Immunotherapy | 2 | 2024 | 641 | 0.230 |
Why?
| | Pyrimidinones | 1 | 2025 | 113 | 0.220 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2025 | 77 | 0.220 |
Why?
| | Tryptophan Oxygenase | 1 | 2024 | 34 | 0.210 |
Why?
| | Uterine Neoplasms | 1 | 2025 | 109 | 0.210 |
Why?
| | DNA Polymerase II | 2 | 2023 | 37 | 0.210 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 35 | 0.210 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 160 | 0.200 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2022 | 17 | 0.190 |
Why?
| | Neoplasms | 3 | 2022 | 2671 | 0.190 |
Why?
| | Radiosurgery | 1 | 2025 | 344 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2023 | 200 | 0.180 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 32 | 0.180 |
Why?
| | Retrospective Studies | 7 | 2025 | 15657 | 0.180 |
Why?
| | Pyrazoles | 2 | 2025 | 423 | 0.170 |
Why?
| | Indazoles | 1 | 2021 | 69 | 0.170 |
Why?
| | Precision Medicine | 1 | 2025 | 429 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2025 | 1993 | 0.170 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 50 | 0.170 |
Why?
| | DNA Mismatch Repair | 3 | 2025 | 49 | 0.170 |
Why?
| | Benzoxazoles | 1 | 2020 | 19 | 0.170 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1389 | 0.160 |
Why?
| | Cerebral Palsy | 1 | 2022 | 107 | 0.160 |
Why?
| | Imidazoles | 1 | 2021 | 238 | 0.160 |
Why?
| | Machine Learning | 1 | 2025 | 493 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 539 | 0.160 |
Why?
| | Azepines | 1 | 2020 | 90 | 0.160 |
Why?
| | Mindfulness | 1 | 2021 | 117 | 0.160 |
Why?
| | Enoxaparin | 1 | 2020 | 63 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2021 | 347 | 0.150 |
Why?
| | Survival Analysis | 3 | 2020 | 1325 | 0.150 |
Why?
| | Margins of Excision | 1 | 2019 | 50 | 0.150 |
Why?
| | Pyridones | 1 | 2020 | 168 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 95 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1396 | 0.140 |
Why?
| | Oncologists | 1 | 2018 | 38 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 2 | 2023 | 916 | 0.140 |
Why?
| | Frozen Sections | 1 | 2018 | 26 | 0.140 |
Why?
| | Recurrence | 1 | 2021 | 1060 | 0.140 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 167 | 0.140 |
Why?
| | Postural Balance | 1 | 2020 | 215 | 0.140 |
Why?
| | Colorectal Neoplasms | 1 | 2025 | 806 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2018 | 5472 | 0.140 |
Why?
| | Pyridines | 1 | 2021 | 506 | 0.140 |
Why?
| | Preoperative Care | 2 | 2017 | 362 | 0.140 |
Why?
| | Cohort Studies | 4 | 2025 | 5742 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 628 | 0.130 |
Why?
| | Pyrimidines | 1 | 2020 | 470 | 0.130 |
Why?
| | Amyotrophic Lateral Sclerosis | 3 | 2003 | 89 | 0.130 |
Why?
| | Minority Groups | 1 | 2018 | 266 | 0.130 |
Why?
| | Gynecology | 1 | 2018 | 168 | 0.120 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 57 | 0.120 |
Why?
| | Perioperative Period | 1 | 2015 | 56 | 0.120 |
Why?
| | Anticoagulants | 1 | 2020 | 664 | 0.120 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 510 | 0.120 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 167 | 0.110 |
Why?
| | Laparotomy | 1 | 2015 | 109 | 0.110 |
Why?
| | Surgeons | 1 | 2018 | 297 | 0.110 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4295 | 0.110 |
Why?
| | Heparin | 1 | 2015 | 261 | 0.100 |
Why?
| | Platinum | 2 | 2025 | 50 | 0.100 |
Why?
| | Quality of Health Care | 1 | 2018 | 642 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2020 | 10811 | 0.100 |
Why?
| | Robotic Surgical Procedures | 1 | 2015 | 130 | 0.100 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 436 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2019 | 1164 | 0.100 |
Why?
| | Paclitaxel | 2 | 2025 | 230 | 0.100 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1236 | 0.090 |
Why?
| | Ovary | 1 | 2013 | 221 | 0.090 |
Why?
| | Prognosis | 5 | 2023 | 4030 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2024 | 2253 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2019 | 3556 | 0.090 |
Why?
| | Postoperative Complications | 2 | 2020 | 2654 | 0.090 |
Why?
| | Maximum Tolerated Dose | 2 | 2022 | 199 | 0.090 |
Why?
| | Chemoradiotherapy | 2 | 2025 | 225 | 0.080 |
Why?
| | Prospective Studies | 4 | 2023 | 7604 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 674 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2015 | 2475 | 0.070 |
Why?
| | Young Adult | 5 | 2025 | 13209 | 0.070 |
Why?
| | Apoptosis | 1 | 2015 | 2553 | 0.060 |
Why?
| | Retreatment | 1 | 2025 | 72 | 0.060 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2025 | 44 | 0.060 |
Why?
| | GPI-Linked Proteins | 1 | 2025 | 73 | 0.060 |
Why?
| | Carboplatin | 1 | 2025 | 144 | 0.060 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.050 |
Why?
| | Adolescent | 5 | 2022 | 21513 | 0.050 |
Why?
| | Wnt4 Protein | 1 | 2024 | 18 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2024 | 181 | 0.050 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2025 | 686 | 0.050 |
Why?
| | Registries | 3 | 2018 | 2035 | 0.050 |
Why?
| | Mesylates | 1 | 2022 | 7 | 0.050 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2022 | 17 | 0.050 |
Why?
| | Tryptophan | 1 | 2024 | 183 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2526 | 0.050 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 197 | 0.050 |
Why?
| | Somatosensory Cortex | 1 | 2022 | 35 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 217 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2024 | 319 | 0.050 |
Why?
| | Ligands | 1 | 2024 | 664 | 0.050 |
Why?
| | Ambulatory Care Facilities | 1 | 2003 | 232 | 0.050 |
Why?
| | Antibodies, Bispecific | 1 | 2022 | 55 | 0.040 |
Why?
| | Magnetoencephalography | 1 | 2022 | 149 | 0.040 |
Why?
| | Quality of Life | 2 | 2025 | 2892 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 840 | 0.040 |
Why?
| | Decision Trees | 1 | 2000 | 93 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 56 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2024 | 778 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 125 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 545 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1477 | 0.040 |
Why?
| | Physical Examination | 1 | 2020 | 241 | 0.040 |
Why?
| | Patient Care Team | 1 | 2003 | 631 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 658 | 0.030 |
Why?
| | Ireland | 3 | 2003 | 30 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2022 | 443 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 898 | 0.030 |
Why?
| | Walking | 1 | 2022 | 529 | 0.030 |
Why?
| | Physical Therapy Modalities | 1 | 2020 | 308 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 872 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 1024 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1547 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2025 | 1238 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2018 | 404 | 0.030 |
Why?
| | Disease Progression | 2 | 2020 | 2757 | 0.030 |
Why?
| | RNA | 1 | 2022 | 921 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 12 | 0.030 |
Why?
| | Salpingectomy | 1 | 2015 | 13 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 21 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 2015 | 101 | 0.030 |
Why?
| | Ovariectomy | 1 | 2015 | 152 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 102 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1972 | 0.030 |
Why?
| | Caregivers | 1 | 2021 | 877 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 2074 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1639 | 0.020 |
Why?
| | Patient Readmission | 1 | 2018 | 697 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5131 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2018 | 786 | 0.020 |
Why?
| | United States | 2 | 2019 | 14841 | 0.020 |
Why?
| | Signal Transduction | 1 | 2024 | 5079 | 0.020 |
Why?
| | Animals | 2 | 2024 | 36940 | 0.020 |
Why?
| | Length of Stay | 1 | 2015 | 1215 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 2012 | 327 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 897 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2003 | 1483 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3295 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1430 | 0.010 |
Why?
| | Mice | 1 | 2020 | 17787 | 0.010 |
Why?
| | Male | 4 | 2020 | 67762 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2003 | 283 | 0.010 |
Why?
| | Child | 1 | 2020 | 21935 | 0.010 |
Why?
| | Central Nervous System Diseases | 1 | 2000 | 69 | 0.010 |
Why?
| | Age of Onset | 1 | 2000 | 518 | 0.010 |
Why?
| | Palliative Care | 1 | 2003 | 758 | 0.010 |
Why?
|
|
Corr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|